FGFR2 and neoplasm: Here we present clinical histories and blood-based biomarker trends for the carbohydrate antigen 19-9 (CA19-9) tumor marker and FGFR2 fusion level measured by FGFR-Dx, a novel FGFR-focused sequencing assay (Fig. 1C).